Targeted Therapies in Prostate Cancer: Emerging Inhibitors and Strategies

Prostate cancer remains one of the most prevalent malignancies affecting men worldwide. Despite advances in diagnosis and conventional treatments such as surgery, radiation, and androgen deprivation therapy, disease recurrence and progression to castration-resistant prostate cancer (CRPC) remain significant clinical challenges. Over the past decade, targeted therapies have emerged as a promising approach to improve patient outcomes by specifically modulating molecular pathways that drive tumor growth, survival, and metastasis.

These therapies focus on inhibiting key signaling cascades, transcription factors, and epigenetic regulators implicated in prostate cancer pathogenesis. Advances in understanding tumor heterogeneity and resistance mechanisms have facilitated the development of novel small-molecule inhibitors, monoclonal antibodies, and combination strategies that precisely target aberrant pathways while minimizing systemic toxicity. Importantly, integrating genomic and proteomic profiling into clinical decision-making allows for personalized therapeutic approaches, optimizing efficacy for individual patients.

This Research Topic aims to highlight the latest developments in targeted therapy for prostate cancer, encompassing preclinical discoveries, translational studies, and clinical applications. Contributions that explore innovative inhibitors, combination regimens, biomarker-guided strategies, and mechanisms of resistance are particularly encouraged.

Key Research Areas Include:

• Novel inhibitors targeting androgen receptor signaling, PI3K/AKT/mTOR, and other critical pathways

• Mechanisms of resistance to targeted therapies and strategies to overcome them

• Biomarker-driven approaches for personalized treatment selection

• Combination therapies integrating targeted inhibitors with immunotherapy, chemotherapy, or radiotherapy

• Advances in drug delivery systems and precision medicine applications

By consolidating current knowledge and emerging findings, this topic seeks to provide a comprehensive overview of targeted therapeutic strategies in prostate cancer, paving the way for more effective and individualized treatments.

Article types and fees

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Data Report
• Editorial
• FAIR² Data
• FAIR² DATA Direct Submission
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• ... View all formats

Articles that are accepted for publication by our external editors following rigorous peer review incur a publishing fee charged to Authors, institutions, or funders.

Article types

This Research Topic accepts the following article types, unless otherwise specified in the Research Topic description:

• Brief Research Report
• Data Report
• Editorial
• FAIR² Data
• FAIR² DATA Direct Submission
• General Commentary
• Hypothesis and Theory
• Methods
• Mini Review
• Opinion
• Original Research
• Perspective
• Review
• Technology and Code

Keywords: Prostate Cancer, Castration-Resistant Prostate Cance, Prostate-Specific Antigen (PSA)

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.